Establishment of an endoscopy-guided minimally invasive murine orthotopic colorectal cancer model by Chen, Chen
 
Aus der Klinik für Allgemein-, Viszeral- und Transplantationschirurgie 
der Ludwig-Maximilians-Universität München 







zum Erwerb des Doctor of Philosophy (Ph.D.) 
an der Medizinischen Fakultät der 




Establishment of an Endoscopy-Guided minimally invasive 















Mit Genehmigung der Medizinischen Fakultät der 













Betreuer:    Prof. Dr. Alexandr V. Bazhin 






































Parts of this work have been published in: 
Chen Chen, Jens Neumann, Florian Kühn, Serene Lee, Moritz Drefs, Joachim Andrassy, 
Jens Werner, Alexandr V. Bazhin, Tobias S. Schiergens* 
―Establishment of an Endoscopy-guided Minimal-invasive Orthotopic Mouse Model of 
Colorectal Cancer‖ 




Table of contents 
 
Abstract ................................................................................................................................ 7 
List of tables ......................................................................................................................... 9 
List of figures ...................................................................................................................... 10 
Abbreviations ..................................................................................................................... 11 
1. Introduction .................................................................................................................... 12 
1.1 Colorectal cancer.................................................................................................. 12 
1.1.1 Tumorigenesis of CRC ............................................................................... 12 
1.1.2 Mechanisms and challenges of metastasis ............................................... 13 
1.2 Mouse models of colorectal cancer metastasis ................................................... 16 
1.2.1 Genetically engineered models ................................................................. 17 
1.2.2 Implantation models ................................................................................... 17 
1.3 Study aims ............................................................................................................ 27 
2. Materials and Methods .................................................................................................. 28 
2.1 Ethical framework ................................................................................................. 28 
2.2 Mice ...................................................................................................................... 28 
2.3 CRC cell lines ....................................................................................................... 29 
2.4 Cell proliferation and cell viability analyses .......................................................... 29 
2.5 Experimental groups ............................................................................................ 30 
2.6 Anesthesia ............................................................................................................ 33 
2.7 Colonic injection in the EGM ................................................................................ 33 
2.7.1 Murine endoscopy ...................................................................................... 33 
5 
 
2.7.2 Endoscopy-guided cell implantation .......................................................... 36 
2.7.3 Follow-up colonoscopy .............................................................................. 39 
2.8 Cecal wall injection in the OSM ............................................................................ 40 
2.9 Autopsy ................................................................................................................. 41 
2.10 Histologic analysis .............................................................................................. 42 
2.10.1 Formalin-fixed and paraffin embedded tissue processing ....................... 42 
2.10.2 Agar-paraffin double embedding technique ............................................. 43 
2.10.3 Hematoxylin and eosin staining ............................................................... 43 
2.10.4 Immunohistochemical staining ................................................................. 45 
2.11 Assessment of tumor infiltrating lymphocytes .................................................... 45 
2.12 Performance parameter of the establishment .................................................... 46 
2.13 Statistical analysis .............................................................................................. 47 
3. Results ........................................................................................................................... 47 
3.1 Performance characteristics ................................................................................. 47 
3.2 Primary tumor growth ........................................................................................... 51 
3.3 Lymph node and distant metastasis ..................................................................... 59 
3.4 Histology and IHC................................................................................................. 60 
4. Discussion ...................................................................................................................... 64 
4.1 Learning curve establishment process ................................................................ 64 
4.2 Primary tumor growth ........................................................................................... 66 
4.3 Lymph node and distant metastasis ..................................................................... 66 
4.4 Assessment of TILs .............................................................................................. 68 
6 
 
4.5 Technical aspects ................................................................................................. 69 
4.6 Limitations ............................................................................................................ 73 
5. Conclusion ..................................................................................................................... 73 
6. References ..................................................................................................................... 74 
Acknowledgement ............................................................................................................. 94 
Affidavit .............................................................................................................................. 96 
Confirmation of congruency ............................................................................................... 97 





























Colorectal cancer (CRC) is a major health problem worldwide and the second leading 
cause of cancer mortality. Murine CRC models play an important role in related research 
and the most widely used orthotopic model represents an open surgical model (OSM) 
using laparotomy. However, the OSM requires advanced surgical skills and creates 
surgical traumas. Thus, this study aimed to establish an endoscopy-guided minimally 
invasive model (EGM) to overcome the inherent defects of the OSM and then compare it 
to the OSM. Murine CRC cell lines including CT26 and MC38 were implanted into BALB/c 
and C57BL/6J mice, respectively. Follow-up colonoscopy was conducted weekly in the 
EGM group. In all animals, gross as well as microscopic examination including 
Hematoxylin and eosin staining and immunohistochemical staining as well as assessment 
of immune cell infiltration were performed. A score of cell injection performance, 
procedure duration and adverse event rates were recorded to analyze the learning curve 
characteristics of both models. In the EGM, the presence of colorectal wall infiltration, 
luminal ulceration, lympho-vascular invasion, tumor-infiltrating lymphocytes were detected, 
as well as spontaneous lymph node, peritoneal and hepatic metastases, while primary 
submucosa infiltration was detected in the OSM, due to surgically injected tumor cells 
originated from the subserosal layer. The primary tumors from both groups showed 
cytoplasmic immuno-staining for Cytokeratin 20. Compared to the OSM, the EGM 
required less time (11.95 ± 5.07 min vs. 33.73 ± 5.24 min, P < 0.001), and less advanced 
surgical skills according to the performance score (1.79 ± 1.12 vs. 2.25 ± 1.29, P = 0.006), 
8 
 
in addition, in EGM, the adverse event rate and the experience level demonstrated a 
significant negative relation (r = − 0.237, P = 0.002), in OSM, Only the rate of wound 
dehiscence was significantly reduced to 0 after the first 20 procedures (P = 0.003), 
abdominal adhesions with bowel obstruction / ischemia was independent of technical 
procedural factors. In conclusion, when compared to the OSM, the presented EGM is able 
to mimic human CRC more closely and tumors can be minimal-invasively and 
longitudinally monitored via colonoscopy. It is easy to learn and can be established quickly 





















List of tables 
Table 1. Experimental subgroups of the EGM and OSM using with different cell 
numbers for injection as well as observation periods. ........................................ 32 
Table 2. Score sheet of systematic assessment for well-being of mice approved by 
the animal care committee for this study. ........................................................... 38 
Table 3. Follow-up colonoscopy evaluation of mice in the EGM groups. .................. 39 
Table 4. Leica TP1020 tissue processor protocol. ..................................................... 42 
Table 5. H&E staining protocol. .................................................................................. 44 
Table 6. Characteristics of the CT26/BALB/c group in the EGM.  ............................ 53 
Table 7. Characteristics of the MC38/C57BL/6J group in the EGM. .......................... 54 
Table 8. Characteristics of the CT26/BALB/c group in the OSM. .............................. 55 

















List of figures 
Figure 1. UICC TNM staging of CRC. ........................................................................ 14 
Figure 2. Experimental setup of the EGM and OSM.................................................. 35 
Figure 3. Performance characteristics during the establishment process of the EGM 
and the OSM of CRC. ......................................................................................... 50 
Figure 4. Representative images of primary tumors from gross autopsy in both 
models. ................................................................................................................ 52 
Figure 5. Growth kinetics of primary tumors in both EGM and OSM. ........................ 57 
Figure 6. Representative images showing metastasis detected during gross 
examination in EGM. ........................................................................................... 59 
Figure 7. H&E and IHC staining of primary tumors in both models. .......................... 62 
Figure 8. H&E staining of metastases in both models. .............................................. 63 
Figure 9. Examples of stromal tumor-infiltrating lymphocytes in EGM. ..................... 63 
Figure 10. Troubleshooting. ........................................................................................ 71 
















ATCC    American Type Culture Collection  
BLI     Bioluminescence imaging 
CIMP    CpG island methylator phenotype  
CK20    Cytokeratin 20 
CRC     Colorectal cancer 
DMEM    Dulbecco's Modified Eagle Medium 
DPBS    Dulbecco's phosphate-buffered saline  
DSMZ    Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 
DSS     Dextran sodium sulfate  
EGM    Endoscopy-guided model 
FBS    Fetal bovine serum 
GEMM     Genetically engineered models 
H&E    Hematoxylin and eosin 
IHC     Immunohistochemistry  
MRI     Magnetic resonance imaging 
MSI     Microsatellite instability  
OSM    Open surgical model 
PET-CT    Positron emission tomography–computed tomography  
RPMI    Roswell Park Memorial Institute Medium 
SD     Standard deviation 




1.1 Colorectal cancer 
Colorectal cancer (CRC) is the fourth most common cancer (after lung, breast and 
prostate cancers), more worryingly, the second leading cause of cancer-related mortality 
worldwide. It was accounted for approximately 10% of total cancer cases and 8.5% of all 
cancer deaths in 2018 (1).  
1.1.1 Tumorigenesis of CRC 
CRC is a disease of modernity. The highest incidence is mainly found in developed 
countries and the number of CRC patients is increasing in countries undergoing economic 
growth (2). Risk factors include genetic predisposition, high-fat diet, obesity, tobacco 
smoking, large intake of red and processed meat, alcohol consumption, and certain forms 
of micriobial dysbiosis (3-13).   
Both colon and rectum consist of four layers: the mucosa, the submucosa, the muscularis 
propria and the serosa. As the inner lining of the colon and rectum, the mucosa is made 
up of the epithelium (a thin layer of columnar epithelial cells), the lamina propria (a layer of 
connective tissue) and the muscularis mucosa (a thin layer of muscle). The epithelium of 
the normal colon and rectum undergo continuous renewal, and the crypts which are 
finger-like invaginations consisting of columnar epithelial cells are the places for cellular 
reproduction. The adenomas is known as benign outgrowths of epithelium, and 
adenocarcinomas which account for most CRC are characterized by malignant glandular 
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epithelial cells invading through colorectal wall layers (muscularis mucosa, sumbumosa, 
muscularis propria), 10%-20% adenocarcinomas may show a mucinous component (14). 
Various assumptions have been proposed for CRC development and progression, and  
the adenoma-carcinoma sequence (adenomatous pathway) is widely accepted as the 
classic description of colorectal carcinogenesis based on several studies, it was 
demonstrated as follows: dysplastic adenomas are the most common form of 
premalignant precursor and can eventually acquire invasive potential (15-19). The 
multistep process of CRC is based on APC gene mutation, KRAS gene mutation and 
inactivating mutations of the TP53 gene, the characteristic genetic changes are often 
accompanied by chromosomal instability (CIN). And major molecular alterations of the 
serrated pathway include BRAF gene mutation, microsatellite instability (MSI) and CpG 
island methylator phenotype (CIMP) (12, 14, 20). 
1.1.2 Mechanisms and challenges of metastasis 
CRC patients without metastasis have a high chance to be cured, however, 40%-50% of 
all CRC patients either develop synchronous (at the time of initial diagnosis) or 
metachronous (in the course of their disease) metastasis (21, 22). In order to better 
determine a patient’s prognosis and the course of treatment, cancer staging system was 
introduced and the UICC 8
th
 edition TNM staging system (Figure 1) of the International 
Union Against Cancer (UICC) is now the globally recognized standard for CRC staging 
(23-26). In this staging system, ―T‖ is defined as the local extent of the primary tumor, ―N‖ 










Metastasis is the process whereby cancer cells spread throughout the body from a 
primary site, to a distant organ. It consists of sequential, interlinked and selective steps 
which include: primary tumor growth, angiogenesis, epithelial-to-mesenchymal transition 
(EMT), invasion, intravasation, survival in circulation, extravasation, dormancy and 
secondary tumor growth at the distant site. The EMT process provides stationary and 
polarized epithelial cells with motility which has been revealed to play a critical role in 
epithelium-derived carcinomas metastasis. During EMT process, stationary and polarized 
epithelial cells lose their cell–cell adherence and apical–basal polarity, thus acquire 
certain mesenchymal characteristics such as enhanced migratory capacity, invasiveness 
and elevated resistance to apoptosis. In CRC, EMT has been revealed to play a critical 
role in epithelium-derived carcinomas metastasis (21, 28, 29). 
While some variability exists on the organs of metastasis among patients with different 
kinds of cancers, it is well known that particular cancers have propensity to form 
metastases in specific organs (organotropism). CRC typically metastasizes to the liver 
(most frequent site of metastasis) and/or lung (30). The theory behind the organ-specific 
pattern of metastasis has not been fully understood yet. Currently, the generally accepted 
explanations are that the portal drainage of the colorectal blood is partially responsible for 
the high rate of liver metastasis as well as the ―seed and soil‖ hypothesis proposed by 
Stephen Paget (31). According to that the non-random pattern of metastases forms only 
when the seed (affinity of certain tumor cells/tissues) and soil (the milieu of a certain organ) 
are compatible. 
As in many other cancer types, prognosis of CRC patients is determined by metastatic 
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tumor progression in the majority of the cases (1, 32, 33). This emphasizes the 
significance of distant spread in CRC and the need for research on its mechanisms in 
order to target this process in a therapeutic setting. Indeed, the major barrier lying in CRC 
treatment is metastasis, and several key questions still remain unanswered. As issues like 
the role of host microenvironment, the entry and proliferation of disseminated or 
circulating tumor cells, the characteristics of the ―seed‖ cells and the ―soil‖ (secondary 
organ) or the mechanisms controlling metastatic dormancy remain unsolved, metastasis 
related studies on the systemic, cellular and molecular levels are highly imperative for 
cancer research.  
1.2 Mouse models of colorectal cancer metastasis 
While improvements of in vitro or ex vivo models such as cell lines and organoids have 
contributed a lot to CRC research, these strategies are limited by lack of host 
microenvironments (34). Therefore, in vivo models still play an indispensable role in CRC 
progression, metastasis, interaction with the immune system and drug resistance (35). 
The mouse and human exhibit certain similarities regarding genetics, anatomy and 
physiology, therefore over 95% of animal studies are conducted in mice (36, 37). CRC 
develops along the large intestine consisting of colon, and rectum. Murine and human 
large intestines share the same microscopic mural structure including mucosa, 
submucosa, inner circular and outer longitudinal tunica muscularis and serosa layers (38). 
In general, murine CRC models can be grouped as genetically engineered and 
implantation models, and a variety of CRC metastasis models have been generated since 
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mouse models of CRC were introduced 80 years ago (39-41). 
1.2.1 Genetically engineered models 
The genetically engineered mouse models (GEMM) offer the potential to study a particular 
gene during carcinogenesis, however, its high costs, the long latency of tumorigenesis in 
combination with a short lifespan due to growth of small bowel tumors and other 
extra-colorectal manifestations limit their application in CRC research, for instance, the 
widely used Apc mutant mice. Some researchers claimed that unlike the implantation 
models, GEMM enable de novo tumor progression without interference of tumor cell / 
tissue from outside, which may even more closely resemble human CRC. However, 
metastasis was rarely observed in GEMM models which makes this model less suitable to 
study mechanisms of distant spread (42-55).  
1.2.2 Implantation models  
In implantation models, tumorigenic cells or tissues are inoculated, e.g. injected, into the 
murine host. This might involve the inoculation of human (xenograft) or murine (syngeneic 
/ allograft) cells, organoids or tissues (56).  
1.2.2.1 Implantation materials 
Many CRC cell lines have been developed since CRC cells were firstly implanted in mice 
in the 1960s (53), for instance, Caco-2 cells (57), HT29 (58), LS174T (59), SW48 (60), 
SW620 (60), which are all derived from CRC patients. Murine CRC cell lines are also 
available, common examples include MC38 cell line from C57BL/6 mice and CT26 cell 
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line from BALB/c mice, in detail, the MC38 murine cell line was derived from a grade III 
colon adenocarcinoma in a female C57BL/6 mouse which was induced by repeated 
carcinogen 1,2-dimethylhydrazine dihydrochloride injection subcutaneously, the murine 
CT26 cell line was developed from a grade IV undifferentiated colon carcinoma in a 
female BALB/c mice by repeated rectal administration of the carcinogen 
N-nitro-N-methylurethane (61-63).  
Although tumor cell line injection is technically easy to perform and of low costs, these cell 
lines may be genetically far away from their origin due to prolonged in vitro passaging, 
Thus, tumor fragments either from biopsies or previously grown tumors were used to 
overcome this problem, briefly, they are usually cut into 1mm cubes and sutured onto the 
cecal or colonic wall (64). This strategy avoids the changes of tumor cell characteristics 
and represents the inherent heterogeneity of spontaneous CRC, but it is labor intensive 
and sometimes limited by availability of tumor specimens (40).  
The encouraging development of three-dimensional organoids could improve those 
patient-derived xenograft models. Organoids are three-dimensional structures consisting 
of different organ-specific cell types generated exclusively from the culture of primary 
tissues or embryonic / induced pluripotent stem cells using similar processes as occurred 
in vivo, including self-organization and spatially-restricted lineage commitment (65-67). 
Currently, CRC organoid culture is available from both human and murine tissues, and 
implantation of organoid is feasible (35, 68, 69). 
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1.2.2.2 Implantation methods 
1.2.2.2.1 Orthotopic models 
In orthotopic CRC tumor models, tumorigenic material, most often cells, is implanted into 
the colorectal wall of the host (53). Several models feature spontaneous distant 
metastasis. 
1.2.2.2.1.1 Open surgical technique 
The open surgical model (OSM) is the most commonly used method in murine CRC and 
many of these models show distant spread. Usually the cecum is exteriorized following 
laparotomy and represents the implantation site with the aim of primary tumor growth. 
Generally the cecum is easy to identify because of its sudden increase in bowel diameter 
(70). The higher tumor take rate involved in cecum compared to other parts of colon is 
another reason to choose this region as implantation site, just as lower rates of death due 
to intestinal obstruction and the technical possibility to surgically remove tumors to study 
the hosts response (71).  
1.2.2.2.1.1.1 Tumor cell line implantation 
The first murine CRC orthotopic implantation model was established in 1977 (72) where 
10
6
 MCA-38 cells were injected into the distal colon, proximal colon, and cecum of a male 
C57BL/6 mouse, respectively. The lowest tumor take rate was found in the proximal and 
distal colon, while the highest was observed in the cecum (90%). Half of the animals 
developed macroscopic liver and mesenteric lymph node metastases 8-9 weeks after 
injection. From then on, the cecum injection technique has been widely adopted. However, 
20 
 
in the majority of reports, injection was performed into the serosal / subserosal layers 
which does not refer to the original origin of CRC (69, 73-81).  
Alencar et al. (82) established a murine CRC model with injection in the mucosal and 
submucosal layers of the cecum by creating a 1cm bowel loop in the transverse colon and 
a 2.5cm bowel loop in the descending colon using nontraumatic clamps, before cell 
suspension injection, 0.05% trypsin in EDTA was injected into the bowel loops and 
incubated for 30min to facilitate tumor cell implantation. Fourteen days after implantation, 
tumorigenesis occurred in all mice.  
Cespedes et al. injected HCT116, SW620 and DLD-1 into the cecal wall following 
laparotomy (83). The primary tumor take rates of the three cell lines were 75%, 75% and 
88%, respectively. The presence of lymph node, liver and lung metastases were also 
studied. For the HCT116 group, the dissemination rate was 100% (lymph nodes), 67% 
(liver) and 50% (lung). In the SW620 group, all mice developed tumor foci in lymph nodes, 
17% of mice had lung metastasis, while no tumor was found in the liver. In the DLD-1 
group, the dissemination rates were 57% (lymph nodes), 29% (liver) and 29% (lung). 
Terracina et al. injected CT26 cells into the submucosal layer of the cecal wall using a 1mL 
syringe with a 28G needle after cecotomy (84). On day 23 after injection, 23 out of 26 
mice had developed tumors, and all 23 mice developed mesenteric lymph node 
metastases. 
1.2.2.2.1.1.2 Tumor tissue implantation 
Rashidi et al. (85) obtained colon tumor tissue from a patient with poorly differentiated 
adenocarcinoma, one or two fragments (1mm
3
) were implanted into the cecum of 
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recipient mice, where a small area of the cecal serosa was removed in advance. 
Extensive multilobe liver metastases were detected in all mice on day 10 postoperatively, 
and all lymph lodes draining the liver developed metastasis by day 19. 
Jin et al. (86) harvested tumor tissue from a LoVo cell line induced subcutaneous CRC 
model on male BALB/c nu/nu nude mice. Then a colostomy was performed in the cecum 
of 14 nude mice, and tumor fragments were sutured into the submucosa of the stoma. The 
ostomy healed 2 weeks postoperatively, 12 mice developed tumors 3 weeks after 
implantation, 3 mice had mesenteric lymph node metastasis while no metastases were 
found in lung or liver. 
In another study by Seguin et al. (87) a piece of CT26 tumor tissue was sutured onto the 
cecal wall after serosa removal just as the procedures conducted by Endo et al. (88). The 
BALB/c Mice developed primary tumors (ranging from 15 to 20mm
3
) on day 5, however, 
the exact tumor take rate and incidence of metastases were not shown. 
1.2.2.2.1.1.3 Organoid implantation 
O’Rourke et al. engrafted colorectal shApc organoids into the colon mucosa of 
Athymic-Nude-Foxn1
nu
 mice (89). The implantation method was adapted from a protocol 
for the engraftment of APC-inactivated intestinal organoids (90). In brief, transient colonic 
injury was induced by DSS to create a niche facilitating organoids implantation. It was 
revealed that 62% of mice developed tumors 7 weeks after implantation and macroscopic 
liver metastases in 1 out of 6 mice were identified 21 weeks after implantation.  
Fumagalli et al. (68) used intestinal carcinoma organoids derived from VillinCreER
T2
::AKP 
genetic mice. In this study, an epithelial pouch was created by disruption of the muscularis 
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layer of the recipient mice. ThAKP organoids led to a 100% (N=22) primary tumor take 
rate and metastasis formation rate. 
1.2.2.2.1.2 Minimal invasive transanal model 
Although the tumor take rate of OSMs can be very high and thus these models very 
effective, several researchers claimed that surgical stress may lead to decreased immune 
function, especially natural killer cell suppression. This might provide a tumor-friendly 
environment and act as a confounder regarding tumor growth and immunogenicity and 
limit the reliability and feasibility of future research goals of measuring immune responses 
after tumor resection (82, 91-93). Moreover, young-onset CRC are more common in the 
distal large intestine defined as distal to the splenic flexure (including the descending 
colon, sigmoid colon and rectum) (94), while the majority of OSMs mainly focus on the 
proximal large bowel defined as colon segments proximal to the splenic flexure. This 
makes it less suitable for research on young-onset and distally located CRCs (95, 96). 
The introduction of models with transanal injection techniques could overcome these 
problems since they not only feature distal tumor locations but also represent 
non-operative techniques requiring shorter operation time and recovery time for mice. 
This might result in less technical complications such as bowel obstruction or ischemia 
due to adhesions as well as less blood loss (84, 97). 
1.2.2.2.1.2.1 Traditional trans anal implantation techniques 
Kashtan et al. (98) transanally injected CT26 cells, MCA38 cells and LS174T cells into the 
rectal submucosa with a 30G needle. Tumors developed in 87.2% of mice (41/47); in 
detail, 17 out of 22 mice and 20 out of 20 mice in the animal group with murine cell 
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injection (CT26 and MCA38, respectivelly) and in 4 out of 5 mice with the human tumor 
cell line LS174T. While lymph node metastases were only found in 8.5% of all cases (4/47) 
this was limited to the CT26 group, and no metastases were detected in MCA38 and 
LS174T groups. 
Donigan et al. (93) injected CT26 cells into the rectal submucosa using a 29G syringe 
under a magnification of ×100 as described in a previous study (99). A tumor incidence of 
65% and a rate of distant metastasis of 3.3% were reported in this study. 
Except tumor cell lines, tumor tissues can also be implanted transanally. Enquist et al. 
(100) collected 10mm
3
 tumor fragments, which were derived from HCT116 / LS174T 
human CRC cell line induced subcutaneous CRC model on NOD/SCID mice, and sutured 
the tumor fragments onto the rectal mucosa using 4-0 Vicryl sutures. Primary tumors were 
detected via colonoscopy, and lymph node, hepatic and pulmonary metastases were 
found 3 weeks (HCT116 group) and 8 weeks (LS174T group) after implantation. 
1.2.2.2.1.2.2 Enema technique  
Takahashi et al. induced short time colitis by dextran sulfate sodium (DSS) in nude mice 
followed by transanal LS174T cell instillation (101). They noted a 95% tumor incidence in 
the animals’ rectum 2 weeks after instillation while metastasis was not found.  
Kishimoto H et al. used a similar technique (102) with application of acetic acid solution to 
disrupt the epithelium of the rectal mucosa. Subsequently, CT26 cells and HCT-116 cells 
were instilled transanally. All mice developed rectal tumors, lymph node and pulmonary 
metastases were found in over 90% of mice. 
The application of inflammatory agents such as DSS and acetic acid facilitated the 
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induction of rectal tumors at high incidence, suggesting that inflammation enhances tumor 
formation in the mucosa (89, 101). Meanwhile, differing from other CRC models in which 
tumors form in the submucosa and serosa layer, those tumors were growing on the 
surface of the mucosa where human CRC originates. However, this technique limits the 
tumor to the rectum and the massive inflammation represents a rather artificial and 
confounding aspect in this model. 
1.2.2.2.1.2.3 Electrocoagulation technique 
Bhullar et al. (103) used transanal low dose mucosal electrocoagulation of the colorectum 
followed by human (LS174T cells and HT29 cells) and murine CRC cell (CRL2638 cells 
and CRL2639 cells) instillation, respectively. It was revealed that for the group of animals 
with human cell line injection, the tumor take rates were 58% (HT29 group) and 100% 
(LS174T group), respectively. Lymph node and distant metastasis were detected in 10 out 
of 12 and 4 out of 12 mice with HT29 and LS174T, respectively. For the group with murine 
cell injection, the tumor take rates were 100% (CRL2638 group) and 92% (CRL2639 
group), respectively, while lymph node and distant spread were detected in 12 out of 12 
and 6 out of 12 mice with CRL-2638 cell line and CRL-2639 cell line injection, respectively. 
1.2.2.2.1.2.4 Endoscopy-guided minimally invasive model  
In humans, endoscopy is the most important strategy for CRC screening, diagnosis and 
follow up care (104). This technique has been adapted to be used in small animals, i.e. 
mice for research purposes (105). In 2005, Alencar et al. used a fiber optic flexible 
endoscope to detect and characterize CRC tumors in mice (82). Later in 2005, Becker et 
al. introduced the Coloview
®
 system (Karl Storz, Tuttingen, Germany) as tool for rigid 
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endoscopy in mice (106). The authors published detailed protocols for colon pathology 
evaluation, biopsy sampling and methylene blue staining (107). Since then, endoscopy 
has become more and more popular to study CRC in mice (108-115). The advantages of 
this technique include the possibility of chromoendoscopy which enables the 
discrimination between neoplastic and inflammatory changes of the murine colon, in 
addition, CRC progression can be successively monitored with high resolution 
colonoscopy as well as biopsy sampling which was shown to be sufficient for histological 
and molecular analyses without sacrificing animals (106, 107).   
In the setting of murine CRC injection models, the use of endoscopy to inject tumorigeneic 
cells into the colorectal wall was previously reported. Zigmond et al. (105) employed the 
Coloview
® 
system to implant human CRC cell lines (SW620, SW480, LS174T) and the 
murine CRC cell line MC38 into the colonic submucosa. Tumor incidence was 100% in 
surviving mice (95%), while distant metastases were not detected. The same Coloview
®
 
system was also used by Bettenworth et al. (116) for human CRC cell line HT-29 
implantation into NOD/SCID mice. Marked colonic tumors were detected from day 12 after 
implantation, 36 days after implantation, 28.6% of all mice developed liver metastases 
and 14.3% of all mice developed peritoneal metastases. Zhao et al. (117) also used the 
Coloview
®
 system for microinjection of CT26, HT29, and MC38 cells. Four weeks after 
injection, tumor growth was only detected in the HT29 group. 
Except for tumor cell lines, tumor organoids can also be implanted with the help of 
endoscopy. Both mouse and patient derived tumor organoids were delivered to the distal 
colon mucosa by Roper et al. using optical colonoscopy (118, 119). For murine tumor 
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organoids, at week 12 after injection, 15 primary tumors and 3 liver metastases were 
observed in 10 mice. For patient-derived primary CRC organoids, 24 primary tumors were 
revealed 8 weeks after injection and 8 liver metastases were found 12 weeks after 
injection. In addition, bioluminescence imaging (BLI) and fluorescence imaging 
techniques were also used to track primary tumor and metastasis. 
1.2.2.2.2 Models of distant metastasis 
Mouse models with the specific aim to achieve distant metastasis often involve the 
injection of tumorigeneic cells directly into the systemic circulation. Since liver 
(approximately 50% of CRC patients) (120) and lung (approximately 5-15% of CRC 
patients) (121) metastases are the most common sites for distant spread, spleen, portal 
vein and liver parenchyma are often used as injection sites, whereas tail vein injection is 
performed to achieve lung metastasis (53, 122). Although this technique is very fast, 
effective and reproducible in inducing metastasis, it bypasses the steps of primary tumor 
growth with subsequent distant spread thereby eliminating the early stages of the 
metastatic cascade. 
Review of the available CRC models suggests that the optimal models of human CRC 
never exist, different kinds of models focus on various research aims by means of 
mimicking different parts of CRC tumorigenesis. Therefore, it is of vital importance to 
choose models according to different research proposes, and within the framework of 
currently used model, its relative limitations should always be taken into consideration in 
order to analyze data meticulously. In addition, more efforts should be made to develop 
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CRC models which can mimic human CRC more comprehensively and accurately without 
endangering ethics. 
1.3 Study aims 
The aim of the present study was to establish two murine orthotopic CRC injection models, 
the OSM and the EGM. Based on a comprehensive literature research on both techniques, 
we hypothesized that (1) the EGM is easier and faster to establish as compared to the 
OSM, (2) the EGM can more accurately emulate the patterns of primary tumor growth of 
CRC as compared to the OSM based on the injection layer of the colorectal wall, (3) the 
use of endoscopy enables the longitudinal evaluation of CRC development thereby 
reducing the animals’ sample size and thus following the 3R principle of animal research. 
Thus, the specific aims of the study were:  
(1) To establish a minimally invasive murine orthotopic EGM of CRC using the Coloview
® 
system. 
(2) To establish an OSM with injection into the cecal wall as referenced gold standard of 
orthotopic CRC models. 
(3) To compare these models regarding establishment performance (learning curve 
characteristics), primary tumor growth and distant metastasis. 
(4) To compare the characteristics of tumorigenicity and immunogenicity of two murine 
CRC cell lines (MC38 and CT26) being injected in both models, respectively. 
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2. Materials and Methods 
2.1 Ethical framework 
This study was approved by the responsible animal care committee 
(ROB-55.2-2532.Vet_02-17-110). All experiments were performed in compliance with the 
guidelines for animal protection in Germany and those of the Federation of European 
Laboratory Animal Science Associations (123). Cervical dislocation was used for animal 
euthanasia. We followed the ARRIVE guidelines for reporting in vivo studies (124). 
2.2 Mice 
BALB/c mice and C57BL/6J mice aged 10-11 weeks (Charles River, Sulzfeld, Germany) 
were housed in temperature and humidity-controlled rooms (22 ± 2°C, 55 ± 5%) at the 
Walter Brendel Centre of Experimental Medicine (LMU, Germany). The animals were 
housed in groups of five in a Makrolon
®
 type II cages (Tecniplast Deutschland GmbH, 
Hohenpeißenberg, Germany) containing low-dust softwood fiber bedding material. Cage 
bedding change was performed weekly. One red, transparent plastic play tunnel, one red, 
transparent plastic igloo and nesting material were provided in each cage for animal 
enrichment. Animals were maintained in a 12-hour light / dark cycle, provided with normal 
pelleted mouse chow food (ssniff Spezialdiäten GmbH, Soest, Germany) and tap water ad 
libitum. Mice were allowed to acclimatize to the housing conditions and husbandry 
procedures for at least one week prior to the experiment. 
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2.3 CRC cell lines 
Murine CRC cell lines CT26 (American Type Culture Collection (ATCC), Manassas, VA) 
which was generated from BABL/c mice was cultured in Roswell Park Memorial Institute 
medium (RPMI1640, Gibco, Paisley, UK) with 10% fetal bovine serum (FBS, BIOWEST, 
Nuaillé, France) and 1% penicillin-streptomycin (pen-strep, PAN-Biotech, Aidenbach, 
Germany) and MC38 which was generated from C57BL/6 mice, it was a gift from the Wolf 
Lab (Gene Center and Department of Biochemistry, LMU) and was cultured in Dulbecco’s 
modifed Eagle’s medium (DMEM, Gibco, Paisley, UK) with 10% FBS and 1% pen-strep. 
Both cell lines were incubated in a 5% CO2 incubator (Binder GmbH, Crailsheim, 
Germany) at 37°C. CT26 was authenticated by the IDEXX BioAnalytics (Ludwigsburg, 
Germany) and MC38 was authenticated by Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (DSMZ, Braunschweig, Germany) before experiments. 
PCR-based mycoplasma testing was performed at regular intervals (quarterly) on all cell 
lines used. Cells in the log phase were collected using trypsin (Biochrom GmbH, Berlin, 
Germany) and single-cell suspensions were prepared using Dulbecco's Buffered Salt 
Solution (DPBS, PAN-Biotech, Aidenbach, Germany) and kept on ice.  
2.4 Cell proliferation and cell viability analyses 
Cell proliferation was examined using EZ4U cell proliferation assay (Biomedica 
Medizinprodukte GmbH, Vienna, Austria) according to manufacturer’s instructions. Briefly, 
100μL cell suspension (4×10
3
 cells) were seeded into each well of 96-well microtiter 
plates and grown for specified time periods (12, 24, 36, 48, 72, 84 and 96h). Subsequently, 
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cells were treated with dye solution for 2h in 37°C incubator. After incubation, the plate 
was removed from the incubator. Absorption was measured at both, 450nm and 492nm 
with 620nm as a reference on a VersaMax Microplate Reader (Molecular Devices, 
Biberach an der Riss, Germany). 
CASY cell counting technology was used to evaluate cell viability, only aliquots with 
a viability of at least 90% were injected. Cells in the log phase were collected and 






/50μL) and then 
kept on ice. Before implantation, the viability was determined using the CASY Cell 
Counter & Analyser System (OLS OMNI Life Science, Bremen, Germany) according to 
the manufacturer’s instructions. 
2.5 Experimental groups 
In a prospective study, the study aims specified in 1.3 were tested by experiments using 
216 mice overall. The outcome measures determined by the study included 
establishments of both EGM and OSM; comparison of the two models regarding 
establishment performance (learning curve characteristics), primary tumor grwoth and 
distant metastasis; comparison of the characteristics of tumorigenicity and 
immunogenicity of two murine CRC cell lines (MC38 and CT26) being injected in both 
models, respectively.  
The number and distribution of mice in each experimental group are shown in Table 1. A 
subgroup size of four animals was granted by the animal care committee. Animals were 
allocated into treatment groups by randomly picking numbers out of a box and the groups 
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were indicated using cage labels. The researcher establishing models and evaluating 
results (i.e., injection of cells, administration of analgesic agent, performing tumor volume 
measurement, etc.) was unaware of the allocation of treatment groups which was 
implemented by masking cage labels before each treatment session. Blinding procedures 





































Table 1. Experimental subgroups of the EGM and OSM using with different cell numbers 
for injection as well as observation periods.  
Group














2 2 1  
1.1.2 2 2 2  
1.1.3 2 2 3  




2 2 1  
1.2.2 2 2 2 
1.2.3 2 2 3 




2 2 1 
1.3.2 2 2 2 
1.3.3 2 2 3 















2 2 1 
2.1.2 2 2 2 
2.1.3 2 2 3 




2 2 1 
2.2.2 2 2 2 
2.2.3 2 2 3 




2 2 1 
2.3.2 2 2 2 
2.3.3 2 2 3 







1 1 1 
Blank control
C
 - 1 1 - 
A
 All experiments were carried out using two murine CRC cell lines, respectively. 
B 
For negative controls, 50μL DPBS without cells were injected 
C 






Medetomidine (0.5mg/kg, Zoetis, Berlin, Germany), midazolam (5mg/kg, rationpharm 
GmbH, Ulm, Germany) and fentanyl (0.05mg/kg, Albrecht GmbH, Aulendorf, Germany) 
were mixed in one syringe (total volume: 2.5mL/kg) and administered via intraperitoneal 
injection for anesthesia. Animals were then observed for 3-7min in their home cages to 
allow time for the animals to calm down in an accustomed environment and the drugs to 
take effect. The depth of anesthesia was assessed by pinching the animal’s toe, if there 
was no withdraw reflex with toe pinch (stage of surgical tolerance), experiments were 
performed. Mice were placed on a heated pad (Witte+Sutor GmbH, Murrhardt, Germany) 
to minimize heat loss caused by anesthesia and ophthalmic ointment (Bepanthen® 
Augen- und Nasensalbe, Bayer Vital GmbH, Leverkusen, Germany) was applied to 
prevent corneal dryness and trauma during anesthesia (125).  
After completion of interventions, surgery or endoscopy, anesthesia was antagonized by 
intraperitoneal injection of naloxone (1.2 mg/kg, ratiopharm GmbH, Ulm, Germany), 
flumazenil (0.5 mg/kg, Inresa Arzneimittel GmbH, Freiburg, Germany) and atipamezole 
(2.5 mg/kg, Vetoquinol GmbH, Ismaning, Germany) mixed to a volume of 8.5 mL/kg body 
weight. Subsequently, mice were kept on the heated pad and carefully returned to their 
home cages until full recovery. 
2.7 Colonic injection in the EGM 
2.7.1 Murine endoscopy 
For murine endoscopy, the Coloview
®
 system (Karl Storz, Tuttlingen, Germany) was used. 
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In detail, a flexible injection catheter (inside diameter 0.28mm, outside diameter 0.61mm, 
Smiths Medical International Ltd., Kent, UK, Figure 2B) with a 31G needle (Figure 2B) 
fixed to the end was introduced into the working channel (Figure 2B) of the sheath. The 
camera (Figure 2A), air infuser (Figure 2A) and light cable (Figure 2A) were assembled to 
the telescope. Usually a light intensity of 70% of the maximum was sufficient for 
endoscopy procedures and in order to avoid bias it was not changed during experiments. 
The white balance was automatically adjusted by pointing the endoscope directly at a 
white object (such as a piece of paper) which was at a distance of 3–5mm and the focus 
was set by rotating the focus ring until the object 3-5cm away is sharp. The valve of the 
Luer lock adapter (Figure 2B) was adjusted to obtain suitable inflation rate, until a slow 
constant air flow was observed in water of a Falcon 50mL conical centrifuge tube (Corning 









Figure 2. Experimental setup of the EGM and OSM.  
(A) Overview of the workplace for murine endoscopy. The camera, air infuser and light 
cable are assembled to the endoscope. (B) For cell injections in the EGM, a flexible 
injection catheter with a 31G needle fixed to the end was introduced into the 3Fr. working 
channel of the 9Fr. examination sheath via a white rubber cap to avoid air leakage, the 
valve of the Luer lock adapter was used for inflation adjustment. The injection position and 
location of each identified tumor were recorded based on the gradations (red asterisk) on 
the endoscope sheath with / without working channel. In the OSM (C), the cecum was 
exteriorized following laparotomy and a characteristic lifting sign indicated successfully 
injection. The abdominal wall was finally closed using 4-0 absorbable sutures (D). (E) 
Murine anatomy of the gastrointestinal tract (126) showing the injection sites of the 









The anesthetized mouse was positioned supine on the heated pad and immobilized by 
adhesive tape. Warm DPBS (1-2mL) was gently applied via a transfer pipette (nerbe plus 
GmbH & Co. KG, Winsen/Luhe, Germany) to wash the colon (127). As the scope was 
gently introduced into the colon, the abdomen was carefully monitored to avoid 
over-inflation since the insufflated intestine could be seen clearly from outside and to 
localize the tip of the scope with transillumination to avoid over-insertion of the scope. 
Colonic mucosa was thoroughly examined during colonoscopy to ensure its health prior to 
cell implantation.   
2.7.2 Endoscopy-guided cell implantation 
For tumor cell injection, the colonic mucosa was gently penetrated by a 31G needle, with 
its bevel directed towards the lumen, then 50μL single tumor cell suspension was injected 
slowly using the Omnican® F syringe (B. Braun Melsungen AG, Hessen, Germany) 
attached to the other side of the catheter. Blood vessels were carefully avoided when 
choosing the injection site, since tumor cells injected into a blood vessel or near a 
damaged blood vessel could cause intravascular dissemination thus distant metastasis. A 
characteristic lifting sign (128) of the mucosa during injection indicated successful 
implantation, the needle was withdrawn 10s after injection to make sure that all cells were 
injected inside. If the initial submucosal injection failed, another three attempts were 
allowed to undertake. The first attempt should be more proximal, then the needle could be 
moved distally for further attempts (118, 119). For negative controls, DPBS were injected 






 cells per 
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50μL injection volume) and four different observation periods (7d, 14d, 21d, 28d) were 
chosen. The injection position was recorded based on the extent to which the endoscope 
was inserted by using gradations on the endoscope sheath with working channel (Figure 
2B). The endoscope and the 31G needle were disinfected using gigasept® AF forte (2% 
v/v, Schülke & Mayr GmbH, Norderstedt, Deutschland) followed by water rinse each time 
before and after use. 
After tumor cell implantation, the animals’ pain, harm or suffering were assessed everyday 
according to the standardized score sheet (Table 2) until the end of the experiment. 
Analgesics (Rimadyl, Zoetis Deutschland GmbH, Berlin, Germany, 5 mg/kg) were injected 
subcutaneously under any of the following circumstances: repeatedly lick / bite / scratch a 





Table 2. Score sheet of systematic assessment for well-being of mice approved by the 
animal care committee for this study. 
Parameter Evaluation criteria Score 
Outer 
appearance 
 Soft and shiny fur, clean body orifices, clear and bright 
eyes 
0 
 Fur loss, slight piloerection, slightly unkempt coat, 
unkempt body orifices, cloudy eyes 
5 
 Marked / prolonged piloerection, sticky / damp body 
orifices, abnormal posture / gait 
10 
 Cramps, paralysis, dyspnea 20 
Behavior 
 Normal behavior 0 
 Reduced activity, hyperactivity 10 
 Reduced interaction with other mice, reduced food 




 Unaffected: vertebral body and pelvic bone not visible 




 Weight loss < 10%, vertebrae and pelvic bone are 
discreetly visible and palpable without pressure 
5 





 Weight loss > 19%, skeletal structure and intervertebral 








 Normal 0 
 Hypothermia or elevated temperature (< 2°C deviation 
from normal temperature), dyspnea, palpable tumors 
present (diameter < 1.5cm) 
10 
 Severe hypothermia / fever (> 2°C deviation from normal 
temperature), tachypnoea, diameter of a palpable 







 Load level 0 0 
 Load level 1 = low load, daily check is required 1-10 
 Load level 2 = moderate load, consultation with 
veterinarians 
11-19 
 Load level 3 = high-grade load, humane endpoints > 20 
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2.7.3 Follow-up colonoscopy 
Tumorigenesis in mice of the EGM groups was monitored weekly by follow-up 
colonoscopy under anesthesia using the same endoscopic system. The average length of 
insertion was 4cm. Further introduction of the endoscope was limited by the colon’s sharp 
angle at the splenic flexure (Figure 2E). Comparable to human endoscopy, the endoscope 
was gently inserted and subsequently gradually withdrawn over time. The position 
(distance from anal verge) of each identified tumor was recorded based on the gradations 
on the endoscope sheath without working channel (Figure 2B). For semi-quantitative 
tumor assessment, the Becker scoring system (107) was used: tumor just detectable 
(score 1), tumor’s size / diameter = 1/8 of the lumen diameter (score 2), 1/4 (score 3), 1/2 
(score 4) or > 1/2 of the diameter (score 5). Changes in the transparency of the colon, 
mucosal bleeding, focal lesions as shown in Table 3 were also recorded. 
 
Table 3. Follow-up colonoscopy evaluation of mice in the EGM groups. 
Wall transparency 
 Normal 
 Most small vessels are invisible 
 Only large vessels are visible 
 Most blood vessels are invisible 
Mucosal bleeding 
 No bleeding. 
 Slightly bleeding 
 Significantly bleeding 
Focal lesions 
 Normal, no focal lesions 
 Redness or erosion 









The tumor was scored according to the Becker scoring system (107) 
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2.8 Cecal wall injection in the OSM 
The animal’s lower abdomen was shaved with an electric shaver (Aesculap Suhl GmbH, 
Suhl, Germany) under anesthesia. The mouse was strapped to the heating pad as 
described above and laparotomy was performed. Briefly, a small nick (1mm) was made in 
the skin, through which the abdominal musculature was grasped and lifted up, then the 
abdominal cavity was entered to extend the incision to 1-2cm using a small scissor. The 
cecum was exteriorized following laparotomy using sterile pre-cut gauze (Figure 2C) and 
warm normal saline solution (Fresenius Kabi Deutschland GmbH, Bad Homburg, 
Germany) was used to keep the cecum always moist. The cecum was gently smoothened 
by atraumatic forceps. For subserosal injection, a 0.3mL insulin syringe with a 31G needle 
attached (Becton, Dickinson and Company, NJ, USA) was used. Under a surgical 
microscope (Zeiss Stemi DV4 SPOT, Carl Zeiss, Göttingen, Germany), cell suspension 
was injected slowly in the submucosal space. The submucosally placed needle could be 
visually identified underneath the thin translucent membrane and at the same time above 
blood vessels. Blood vessels were carefully avoided when choosing the injection site, 
since tumor cells injected into a blood vessel or near a damaged blood vessel could cause 
intravascular dissemination thus distant metastasis. A characteristic lifting sign of the 
serosa during injection indicated successful implantation (Figure 2C). The needle was 
withdrawn 10s after injection to make sure that all cells were injected inside. If the initial 
subserosal injection failed, another three attempts were allowed to undertake. Distilled 
water was then used to thoroughly rinse the cecum with to lyse possibly leaked tumor 
cells in order to prevent artificial peritoneal tumor cell dissemination. After water rinse, the 
41 
 
cecum was returned back to the abdominal cavity and the abdominal wall was closed with 
4-0 absorbable sutures (VICRYLTM Plus, Johnson & Johnson Medical Devices 
Companies, Diegem, Belgium), specifically, the simple continuous suture was used for 
peritoneal closure and the simple interrupted suture was used for skin closure (Figure 2D). 
The povidone iodine (MUNDIPHARMA GmbH, Frankfurt am Main) was applied to the 
surgical area both before and after laparotomy. For negative controls, DPBS was injected 







per 50μL of injection volume) and four different observation periods (7d, 14d, 21d, 28d) 
were chosen. 
After tumor cell implantation, the animals’ pain, harm or suffering were assessed everyday 
according to the standardized score sheet (Table 2) until the end of the experiment. 
Follow-up colonoscopy was not performed in the OSM group. Rimadyl was injected 
subcutaneously under any of the following circumstances: repeatedly lick / bite / scratch a 
particular body part; automutilation; curved back; raised abdomen; visible pedicle. 
2.9 Autopsy  
A complete autopsy was performed right after sacrifice according to Prof. Treuting’s 
guideline (129). Any tissue showing evidence of neoplasm or other abnormality was 
sectioned for histological examination, in particular, abnormal livers (livers with decreased 
volume / harden liver tissues) were collected sectioned carefully in order not to miss 
hepatic metastasis. The location, number as well as the size of the tumors and 
metastases were recorded. The tumor volume was determined based on the formula 
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Volume = (length × width
2
)/2, whereas the length was the largest tumor diameter and the 
width represented the smallest perpendicular tumor diameter (130).  
2.10 Histologic analysis 
2.10.1 Formalin-fixed and paraffin embedded tissue 
processing 
Immediately after sacrifice, all organs of interest were harvested and fixed for 12-72h 
depending on the size of the tissue in 4% neutral buffered formaldehyde solution 
(SAV-Liquid-Production, Flintsbach am Inn, Germany) at room temperature (RT). The 
samples were then washed under running tap water for 2h and transferred to 70% ethanol 
and processed by a Leica Dehydrator Tissue Processor TP1020 (Leica Microsystems Ltd., 
Shanghai, China) according to manufacturer’s protocol (Table 4). After dehydration 
tissues were embedded in paraffin blocks and RT. 
 
Table 4. Leica TP1020 tissue processor protocol. 
Reagent Incubation time (min) 
70% Ethanol 120 
70% Ethanol 120 
70% Ethanol 60 
96% Ethanol 90 
96% Ethanol 90 
100% Ethanol 90 
100% Ethanol 90 









2.10.2 Agar-paraffin double embedding technique 
Embedding tissues in agar prior to tissue processing is very beneficial when working with 
small and friable samples which was performed according to a previous study (131). A 2% 
agar solution (w/v, BactoTM Agar, Becton, Dickinson and Company, NJ, USA) was 
prepared in DPBS and incubated in a water bath at 45
o
C to prevent from solidification. 
Briefly, tissues were washed with DPBS 3 times (15min each) after formalin fixation. The 
appropriate sized moulding was filled with 2% agar solution in which the tissue was 
immediately placed in and orientated correctly. After the agar block became solid, it was 
detached from the moulding and trimmed as required leaving a 3-5mm width of agar 
surrounding the tissue.  
2.10.3 Hematoxylin and eosin staining 
For Hematoxylin and eosin (H&E) staining, 5µm sections were cut with a Leica Microtome 
RM 2255 (Leica Microsystems Nußloch GmbH, Nußloch, Germany), transferred to a 46°C 
water bath and fixed on microscope slides (Paul Marienfeld GmbH & Co. KG, 
Lauda-Königshofen, Germany). The paraffin sections were deparaffinized, stained and 
dehydrated according to Table 5, and the coverslips were mounted onto the sections with 
non-aqueous EUKITT® mounting media (ORSAtec GmbH, Bobingen, Germany). The 
mounted slides were then examined using an Olympus BX40 Clinical Microscope 
(Olympus Optical Co., Ltd, Tokyo, Japan) after the mounting medium was fully hardened. 
Image acquisition was conducted with a Carl Zeiss AxioCam MRc5 Microscope CCD 
Camera (Carl Zeiss, Göttingen, Germany) and Zen 2 lite software. 
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Table 5. H&E staining protocol. 
Reagent Incubation time 
NeoClear 10min 
NeoClear 10min 
99% Ethanol 5min 
99% Ethanol 5min 
96% Ethanol 5min 
96% Ethanol 5min 
70% Ethanol 5min 
70% Ethanol 5min 
Distilled water 5min 
Tap water 2 dips 
Filtered Hematoxylin
A 




Running tap water 5min 
Distilled water 2 dips 
Eosin stain
C 
30s (with gentle shaking) 
Tap water 2 dips 
80% Ethanol 1 dip 
96% Ethanol 1 dip 




Hematoxylin: Mayer’s hemalum solution, Merck KGaA, Darmstadt, Germany 
B 
Acid ethanol: 55mL 1% HCl + 95mL 70% Ethanol 
C 
Eosin stain: 1% alcoholic Eosin Y solution (w/v, Eosin Y disodium salt, Sigma, Merck 










2.10.4 Immunohistochemical staining 
Immunohistochemistry (IHC) was performed on paraffin-embedded sections (4μm thick) 
with the help of Prof. Neumann’s lab (Department of Pathology, LMU). To assess CK20 
expression, sections were deparaffinized and rehydrated. Heat mediated antigen retrieval 
was performed in Tris-EDTA (pH 9.0) at 96°C for 20min. Subsequently, the slides were 
blocked with BLOXALL™ Blocking Solution (Vector Laboratories, CA, USA), 5% horse 
serum/TBST, and Avidin/Biotn Blocking Solution (Vector Laboratories), respectively, 
followed by overnight incubation with rabbit anti-mouse CK20 (Anti-Cytokeratin 20 
antibody, Abcam, Berlin, Germany; dilution 1:500) at 4°C. The next day, slides were 
stained with biotinylated horse anti-rabbit IgG (Vector Laboratories) and signals were 
detected using ABC-AP Reagent and AP Substrate (Vector Laboratories). After 
hematoxylin counterstaining, the slides were mounted in aqueous mounting medium 
(Merck, Darmstadt, Germany) and examined using an Olympus BX40 Clinical Microscope 
(Olympus, Tokyo, Japan). The image acquisition was conducted with the digital camera 
Leica DMC4500 (Leica, Wetzlar, Germany) and Leica Application Suite X (LAS X) 
3.6.0.20104 software.  
2.11 Assessment of tumor infiltrating lymphocytes 
Tumor infiltrating lymphocytes (TILs) in both EGM and OSM groups were systematically 
assessed and quantified (132). This was accomplished by two independent observers 
(Chen Chen and Prof. Jens Neumann) based on H&E slides of tumor tissues containing 
the invasive tumor margin, and the Olympus BX40 Clinical Microscope (Olympus Optical 
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Co., Ltd, Tokyo, Japan; Magnification 200X) was used. Both the TIL score (133, 134) and 
the Roche score (135) were recorded. Discrepancies were resolved by re-check and a 
subsequent consensus decision. Regarding the TIL score, only areas of tumor stroma 
were assessed, and the percentage of stromal TILs was classified as: 0-10% = 1, 11-20% 
= 2, 21-30% = 3, 31-40% = 4, 41-50% = 5 and 51-100% = 6. For the Roche score, 
lymphocytes located at the tumor invasive margin, tumor stroma and intra-tumor areas 
were assessed. The immune phenotype was classified as: 1 = immune desert (nearly no 
lymphocytes are present within the invasive tumor margin), 2 = immune-excluded tumors 
(lymphocytes are present at the invasive margin and stroma), 3 = inflamed tumors 
(lymphocytes are also found in the intra-tumor areas). 
2.12 Performance parameter of the establishment 
The performance data from 116 mice (EGM) and 105 mice (OSM) were divided into 
groups of 20 mice in chronological order with the last group (> 100) containing 16 mice 
(EGM) and 5 mice (OSM) and analyzed. Regarding the learning curve analysis, quality 
indicators such as success rate of submucosal injection into the colorectal wall,  
subserosal injection into the cecal wall, adverse event rate, and the duration of each 
procedure were recorded. Successful submucosal / subserosal injection was defined as 
observation of a positive lifting sign of the mucosa / serosa indicating no transmural / 
intracecal injection as well as absence of bleeding at the injection site. Adverse events 
included colon perforation (EGM) which was defined as either colonoscopically detected 
bowel perforation or pneumoperitoneum which was characterized by rapid abdominal size 
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gain, and wound dehiscence and abdominal adhesions with bowel obstruction or ischemia 
(OSM). A performance score was assigned to each mouse based on the total number of 
injection attempts and a score of 5 indicated failure. The duration of procedure was 
counted from the time point of anaesthetic injection to the time point of the endoscope 
removal (EGM) or to the time point of povidone iodine application on the surgical incision 
(OSM). 
2.13 Statistical analysis 
All data were expressed as mean and standard deviation (SD) or as numbers and 
percentages. Categorical data were analyzed using either the Chi-square test or Fisher’s 
exact test. Continuous variables were compared using the student’s t-test and one-way 
ANOVA with the Bonferroni correction applied for multiple comparisons. Correlation was 
assessed using bivariate correlation. P values less than 0.05 were considered statistically 
significant. The data were analyzed using GraphPad Prism (version 8.4.0, GraphPad, San 
Diego, CA) and SPSS (version 23.0, SPSS Inc., Chicago, IL). 
3. Results 
3.1 Performance characteristics  
In EGM group, leakage and perforation of the colon were two reasons of injection failure. 
In OSM group, injection failure was due to leakage and perforation of the blood vessel and 
the sutures were completely absorbed on day 18 ± 7 (n = 6, x ± s) for C57BL/6J mice, and 
day 21 ± 7 (n = 3, x ± s) for BALB/c mice.  
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The performance score, duration of the procedures, and the adverse event rate 
depending on the number of interventions carried out in both models, respectively, are 
shown in Figure 3.  
Up to 4 attempts were made on each mouse until the injection was successful. Overall, 
the rate of successful injection was comparable in both models (performance score < 5, 
94% vs. 91%, P = 0.461), the mean performance score of the EGM regarding all 
procedures was significantly lower than that of the OSM (1.79 ± 1.12 vs. 2.25 ± 1.29, P = 
0.006). For both models, performance score and the number of interventions carried out 
so far showed a significant negative correlation, although the correlation was weak (EGM: 
r = − 0.197, P = 0.006; OSM: r = − 0.157, P = 0.032). After 40 procedures, the performance 
score of the EGM significantly decreased (Figure 3A; 2.35 ± 1.42 vs. 1.50 ± 0.78, P = 
0.001), whereas a decrease in the OSM was observed after 60 procedures (2.50 ± 1.384 
vs. 1.91 ± 1.083, P = 0.020).  
Overall, the mean duration of EGM procedures was significantly shorter compared to that 
of the OSM (11.95 ± 5.07 min vs. 33.73 ± 5.24 min, P < 0.001). For both models, the 
duration of the procedure and level of experience (procedures performed so far) showed a 
significant negative relation, although the relation was weak (EGM: r = − 0.144, P = 0.028; 
OSM: r = − 0.184, P = 0.007). After 20 interventions, the duration of EGM procedures 
significantly dropped (15.00 ± 6.95 min vs. 11.31 ± 4.36 min, P = 0.033), while a significant 
reduction in the duration of the OSM was observed occurred after 40 procedures (35.20 ± 
5.10 min vs. 32.83 ± 5.17 min, P = 0.024), however, two long procedures were recorded in 




Regarding adverse events, 7 cases were recorded in the EGM due to colon perforation, 
10 cases were recorded in the OSM derived of wound dehiscence (n=2), abdominal 
adhesions with bowel obstruction / ischemia (n=8). The overall adverse event rate of the 
EGM was comparable to that of the OSM (6% vs. 10%, P = 0.169). In the EGM group, the 
adverse event rate and experience level of the investigator demonstrated a significant 
negative relation (r = − 0.237, P = 0.002). In detail, the mean adverse event rate of the first 
40 procedures was 17.5%, and was significantly reduced to 0 afterwards (P < 0.001). In 
the OSM group, a significant negative relation was not found between the adverse event 
rate and the experience level of the investigator. Only the rate of wound dehiscence was 
significantly reduced to 0 after the first 20 procedures (P = 0.003), abdominal adhesions 





Figure 3. Performance characteristics during the establishment process of the EGM and 
the OSM of CRC. 
(A) The mean performance score, (B) the mean duration of an intervention, and (C) the 
adverse event rate for mice divided into groups of 20 animals with the last group (> 100) 




3.2 Primary tumor growth 
The primary tumor take rate and mortality within the observation period are shown in 
Tables 6-9 for both cell lines and mouse models, respectively. No gender-dependent 
differences in primary tumor growth were observed. Representative images from gross 
examination of mice of both models are shown in Figure 4B-G. The growth kinetics of 
primary tumors in the EGM group were monitored weekly using the Becker’s scoring 
system and representative colonoscopy images showing endoscopic scores of 3, 4, and 5 
are shown in Figure 5B–D. Primary tumor volumes of both models derived from gross 
autopsy are shown in Figure 5G and H, both cell lines were included. Both macroscopic 
and microscopic tumor growth were not detected in the negative controls. For the EGM 
group, the endoscopic scores during follow-up colonoscopy within observation period are 
demonstrated in Figure 5E. For both cell lines, a significant positive correlation was 













Figure 4. Representative images of primary tumors from gross autopsy in both models. 
(A-D) Representative images of the colorectum (yellow arrows: cecum) of mice in the 
EGM group showing various sizes of primary tumors in the distal part of the colorectum, 
and (E-F) the cecum (yellow arrows) of mice in the OSM group showing various sized of 
primary tumors (red arrows) detected during gross examination. 


























Tumor take rate 
[mice(%)] 
Tumor volume 
















7 0/4 (0) 2/4 (50) 2.5 ± 0.7 3.5 ± 0.7 0/2 (0) 0/2 (0) 0/2 (0) 
14 0/4 (0) 4/4 (100) 2.6 ± 1.5 3.3 ± 1.5 3/4 (75) 0/4 (0) 1/4 (25) 
21 0/4 (0) 4/4 (100) 5.8 ± 2.9 2.5 ± 1.3 1/4 (25) 1/4 (25) 0/4 (0) 
28 0/4 (0) 4/4 (100) 20.0 ± 1.6 2.3 ± 1.3 1/4 (25) 0/4 (0) 0/4 (0) 
        
10
5 
7 0/4 (0) 4/4 (100) 4.8 ± 5.2 3.8 ± 1.0 2/4 (50) 0/4 (0) 1/4 (25) 
14 0/4 (0) 4/4 (100) 7.0 ± 7.4 4.5 ± 1.3 4/4 (100) 1/4 (25) 2/4 (50) 
21 0/4 (0) 3/4 (75) 31.0 ± 20.7 3.3 ± 1.5 2/3 (67) 0/3 (0) 0/3 (0) 
28 0/4 (0) 3/4 (75) 22.7 ± 2.3 1.3 ± 0.6 1/3 (33) 0/3 (0) 0/3 (0) 
        
10
6 
7 0/4 (0) 4/4 (100) 31.3 ± 17.7 4.3 ± 1.0 2/4 (50) 0/4 (0) 1/4 (25) 
14 0/4 (0) 4/4 (100) 15.8 ± 8.5 2.8 ± 0.5 2/4 (50) 0/4 (0) 2/4 (50) 
21 3/4 (75)B 4/4 (100) 44.3 ± 45.2 1.3 ± 0.5 2/4 (50) 0/4 (0) 0/4 (0) 
28 4/4 (100)B 4/4 (100) 27.5 ± 11.9 2.3 ± 1.5 2/4 (50) 1/4 (25) 1/4 (25) 
A 
Mice with metastasis / mice with primary tumor growth in the group. 
B 















Tumor take rate 
[mice(%)] 
Tumor volume 
















7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
21 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
28 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
        
10
5 
7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 1/4 (25) 4.0 ± 0.0 1.0 ± 0.0 0/1 (0) 0/1 (0) 0/1 (0) 
21 0/4 (0) 2/4 (50) 2.2 ± 1.3 2.0 ± 1.4 0/2 (0) 0/2 (0) 0/2 (0) 
28 0/4 (0) 3/4 (75) 9.7 ± 5.5 1.7 ± 1.2 2/3 (67) 1/3 (33) 0/3 (0) 
        
10
6 
7 0/4 (0) 0/4 (0) -  0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 2/4 (50) 10.0 ± 8.5 1.0 ± 0.0 0/2 (0) 0/2 (0) 0/2 (0) 
21 0/4 (0) 1/4 (25) 18.0 ± 0.0 1.0 ± 0.0 0/1 (0) 0/1 (0) 0/1 (0) 
28 0/4 (0) 2/4 (50) 14.1 ± 15.5 2.0 ± 1.4 1/2 (50) 0/2 (0) 0/2 (0) 
A 





































7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 3/4 (75) 2.8 ± 2.8 1.0 ± 0.0 1/3 (33) 0/3 (0) 0/3 (0) 
21 0/4 (0) 2/4 (50) 17.0 ± 9.9 1.5 ± 0.7 1/2 (50) 0/2 (0) 1/2 (50) 
28 2/4 (50)
B
 4/4 (100) 15.0 ± 8.1 2.0 ± 0.8 2/4 (50) 2/4 (50) 0/4 (0) 
        
10
5 
7 0/4 (0) 1/4 (25) 1.51 ± 0.0 1.0 ± 0.0  0/1 (0) 0/1 (0) 0/1 (0) 
14 0/4 (0) 4/4 (100) 3.5 ± 2.1 1.8 ± 0.5 1/4 (25) 0/4 (0) 1/4 (25) 
21 1/4 (25)
B
 4/4 (100) 5.3 ± 7.2 2.3 ± 1.0 1/4 (25) 1/4 (25) 1/4 (25) 
28 4/4 (100)
B
 4/4 (100) 17.9 ± 12.6 2.5 ± 1.0 0/4 (0) 1/4 (25) 0/4 (0) 
        
10
6 
7 0/4 (0) 2/4 (50) 7.0 ± 1.4 1.5 ± 0.7 0/2 (0) 0/2 (0) 0/2 (0) 
14 2/4 (50)
B
 4/4 (100) 11.1 ± 10.3 2.3 ± 1.0 1/4 (25) 1/4 (25) 1/4 (25) 
21 3/4 (75)
B
 3/4 (75) 19.6 ± 11.9 2.3 ± 1.5 1/3 (33) 1/3 (33) 1/3 (33) 
28 4/4 (100)
B
 4/4 (100) 41.6 ± 10.1 3.0 ± 1.6 3/4 (75) 1/4 (25) 2/4 (50) 
A 
Mice with metastasis / mice with primary tumor growth in the group. 
B 



































7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
21 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
28 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
        
10
5 
7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
21 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
28 0/4 (0) 1/4 (25) 1.5 3 1/1 (100) 0/1 (0) 0/1 (0) 
        
10
6 
7 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
14 0/4 (0) 0/4 (0) - - 0/0 (0) 0/0 (0) 0/0 (0) 
21 0/4 (0) 1/4 (25) 1.0 4 0/1 (0) 1/1 (100) 0/1 (0) 
28 0/4 (0) 1/4 (25) 1.5 4 0/1 (0) 0/1 (0) 0/1 (0) 
A 






Figure 5. Growth kinetics of primary tumors in both EGM and OSM.  
(A-D) Representative colonoscopy images in the EGM showing the distal colorectum of (A) 
a control mouse and different endoscopic scores of tumor growth: (B) score of 3 (~ 1/4 of 
the lumen), (C) score of 4 (~ 1/2 of the lumen), (D) score of 5 (> 1/2 of the lumen). (E) 
Endoscopic scores assigned during follow-up colonoscopy to CT26/BALB/c and 
MC38/C57BL/6J after injection of different numbers of tumor cells, respectively. (F) Box 
plots of primary tumor volume categorized by the endoscopically assigned score in the 
EGM group. Mean primary tumor volume derived from both tumor cell lines measured at 









In the MC38/C57BL/6J group, no tumor growth was detected in the 10
4
 cell subgroup and 
at 7 days of observation regardless of the cell number injected, tumors in the EGM were 
significantly larger than in the OSM (9.4 ± 7.9 mm
3
 vs. 1.3 ± 0.3 mm
3
, P = 0.007). In the 
CT26/BALB/c group, the same trend was observed, but the difference was not significant 
(P = 0.298). 
Regarding the EGM, a significant positive correlation was revealed between tumor volume 
and observation period (r = 0.342, P = 0.001) as well as the number of injected cells (r = 
0.38, P < 0.001). The injection of high cell numbers (10
6
) led to significantly larger tumors 
as compared to injection of 10
4
 cells (25.8 ± 23.2 mm
3
 vs. 7.9 ± 7.9 mm
3
, P = 0.008) and 
10
5
 cells (25.8 ± 23.2 mm
3
 vs. 12.2 ± 12.9 mm
3
, P = 0.038), respectively. In addition, 
tumorigenicity of CT26/BALB/c group was significantly higher than MC38/C57BL/6J group 
(0.9 ± 0.2 vs. 0.2 ± 0.3, P < 0.001). In the OSM, a positive correlation between tumor 
volume and duration of the observation period was observed (r = 0.399, P < 0.001). 
Tumors in the OSM from the 28 days group were significantly larger than the 7 days group 
(20.1 ± 17.0 mm
3
 vs. 2.2 ± 3.4 mm
3
, P = 0.007) and the 14 days group (20.1 ± 17.0 mm
3
 
vs. 4.8 ± 6.8 mm
3
, P = 0.027), respectively. A significant positive correlation was also 
demonstrated between mortality and duration of the observation period (r = 0.408, P = 
0.025). In OSM group, Compared to the MC38/C57BL/6J, CT26/BALB/c group developed 
significantly larger tumors (14.1 ± 13.8 mm
3
 vs. 1.3 ± 0.3 mm
3
, P < 0.001), higher tumor 
take rate (0.7 ± 0.3 vs. 0.1 ± 0.1, P < 0.001), and the mortality of CT26/BALB/c was 0.3 ± 
0.4, while it was 0 in the MC38/C57BL/6J group. 
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3.3 Lymph node and distant metastasis  
The rate of both, lymph node and distant metastasis, is shown in Tables 6-9 for both 
models and cell lines, respectively, no further metastasis was observed, such as 
pulmonary metastasis or cerebral metastasis. No metastatic growth was found in negative 
controls and animals without primary tumor growth. No gender-dependent differences in 
metastasis rates were observed. Representative images of gross examination are shown 
in Figure 6. 
 
 
Figure 6. Representative images showing metastasis detected during gross examination 
in EGM (128).  
(A) Lymph node metastasis in 10
5
 CT26/BALB/c group, (B) peritoneal carcinosis in 10
5 
MC38/C57BL/6J group and (C) liver metastasis in 10
5 
CT26/BALB/c group. All 






In EGM, there was a trend regarding negative correlation between metastasis rate and the 
observation time (r = -0.002, P = 0.985), in addition, a trend towards a positive correlation 
was seen between metastasis rate and the injected cell number (r = 0.114, P = 0.363). 
The CT26/BALB/c group revealed a significantly higher overall metastasis rate compared 
to the MC38/C57BL/6J group (0.2 ± 0.3 vs. 0.1 ± 0.2, P = 0.035). In CT26/BALB/c group, 
lymph node metastases were only absent from the subgroup of 10
4
 cells and the 
subgroup of 7 days observation; peritoneal carcinosis was found in 3 animals of the 
CT26/BALB/c group; hepatic metastases were found in 18% animals which developed 
primary tumors (Table 6). In the MC38/C57BL/6J group, lymph node metastases were 
only detected in 3 animals on day 28 when more than 10
4
 cells were injected (Table 7); 
peritoneal carcinosis only occurred in one animal; no distant spread was observed. 
In the OSM, there was a significant positive relation between metastasis rate and 
observation time (r = 0.274, P = 0.033), both the 14 days and the 28 days observation 
groups demonstrated significant higher metastasis rate as compared to that of the 7 days 
observation group, respectively (0.13 ± 0.14 vs. 0, P = 0.044; 0.26 ± 0.29 vs. 0, P = 0.040). 
Hepatic metastases were found in 20% mice in CT26/BALB/c group, while none was 
detected in MC38/C57BL/6J. 
3.4 Histology and IHC  
Representative H&E as well as IHC staining of primary tumors and metastases are shown 
in Figures 7 and 8. All EGM derived tumors showed a comparable microscopic malignant 
phenotype with a moderate atypia of the nuclei. As morphologic characteristics, infiltrating 
61 
 
growth into the colorectal wall and lympho-vascular invasion was noticed (Figure 7A-D). In 
addition, luminal ulceration of primary tumors was observed frequently. In the OSM, 
infiltrating growth into the muscularis mucosa was observed (Figure 7E and H). 
In the EGM, the TIL score of the CT26/BALB/c group was significantly higher than the 
MC38/C57BL/6J group across all subgroups (3.0 ± 1.4 vs. 1.5 ± 0.9; P = 0.003), while the 
OSM revealed opposite results (MC38/C57BL/6J vs. CT26/BALB/c = 3.7 ± 0.6 vs. 2.1 ± 
1.0; P = 0.012). A negative correlation between TILs-score and general metastasis was 
observed in the OSM (r = -0.331, P = 0.028).  
Tumors of both EGM and OSM showed cytoplasmic positivity for CK20 (Figure 7G and H) 











Figure 7. H&E and IHC staining of primary tumors in both models. 
(A and B) One week after submucosal injection (10
6
 CT26 cells) in EGM, the malignant 
tumor with moderate atypia of the nuclei shows luminal ulceration (A, yellow arrow) and 
infiltration of the muscularis propria layer (red arrows) corresponding to a pT2-category in 
humans. (C and D) Representative images of the lympho-vascular invasion (red arrow) in 
EGM corresponding to a L1-category in humans near primary tumor site. (E and F) One 
week after subserosal injection (10
6
 CT26 cells) in OSM, the tumor cells located in the 
space between the muscularis mucosa and the muscularis externa of the cecal wall. (G 





Figure 8. H&E staining of metastases in both models. 
(A and B) Mesenteric lymph node metastasis with tumor infiltrates (red arrows) and 
necrosis (yellow arrows) in OSM. (C and D) Hepatic metastasis with tumor infiltrates (red 
arrows), normal liver tissue (yellow arrows) in EGM. 
 
 
Figure 9. Examples of stromal tumor-infiltrating lymphocytes in EGM.  
Scoring of stromal tumor-infiltrating lymphocytes (yellow circles) with a score of 1 (0–10% 






In the present study, a syngeneic endoscopy-guided minimally invasive orthotopic murine 
CRC model was established. When compared to the OSM as the gold standard, the EGM 
was found to be easier to learn, faster to perform, be associated with less complications 
and more effective regarding local tumor growth with colorectal wall infiltration, luminal 
ulceration as well as the presence of lympho-vascular invasion. In the current work, the 
results of two syngeneic approaches (CT26/BALB/c and MC38/C57BL/6J) with 
application of specific cell concentrations and choosing specific observation periods are 
shown which could provide guidance for defined experiment settings based on the 
scientific aim. 
The OSM has been the most commonly used method in murine orthotopic CRC 
implantation models, however this model requires advanced surgical skills and creates 
surgical traumas (81). Therefore, since endoscopy was first introduced to mice by Alencar 
et al. (82) and Becker et al. (106), many attempts have been made in developing EGM 
which could overcome the drawbacks of OSM. Our study used both CT26/BABL/c and 
MC38/C57BL/6J syngeneic approaches to establish an EGM. 
4.1 Learning curve establishment process 
The amount of surgical or technical training required to achieve technical competence for 
both orthotopic injections models presented in this study is unknown despite increasing 
demand to train researchers in these procedures. In the medical literature no data on 
characteristics of such a challenging establishment process is available, however, in 
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communication with our collaborators, we anecdotally heard of technical difficulties in both 
models resulting in low research efficacy. Therefore, characterization of the establishment 
process by assessing parameters of the learning curves was one aim of the present study. 
Overall, the performance got better as interventions accumulated by time, however, in the 
OSM group, only the rate of wound dehiscence was significantly reduced to 0 after the 
first 20 procedures, the abdominal adhesions with bowel obstruction / ischemia may 
always exist at a rate of 7% regardless of the amount of training, which could have 
occurred due to bleeding, infection or inflammation. Regarding the technical problems or 
adverse events in the OSM, related details were only found in two studies. The technical 
difficulty of the surface injection on cecal wall was mentioned in both studies. In addition, it 
was observed in one study, that the submucosal injection on the cecal wall could cause 
early peritoneal carcinosis, which was due to the leaked tumor cell suspension through 
the tract of the injection needle (84). In the other study, a complication rate of 19.6% was 
detected during as well as after the procedures, including inflammation of the injection site, 
leakage of bowel content, and abdominal bleedings (97). The adverse event rate in our 
EGM was significantly reduced to 0 after the first 40 procedures. Perforation was the only 
observed adverse event which may be involved in over-inflation and / or intra-luminal 
injection. Few data are available on complications during murine endoscopy. Zigmond et 
al. reported a complication rate of 5% including perforation and cell leakage to the 
peritoneal cavity (105). Plummer et al. demonstrated 5% perforation rate (136). Those 
results are in line with ours in the present study (6%). 
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4.2 Primary tumor growth 
In both models, the CT26/BABL/C group showed significantly higher tumor take rates in 
comparison with the MC38/C57BL/6J group, respectively and more cells were required to 
initiate tumorigenesis in the MC38/C57BL/6J groups compared to the CT26/BABL/C 
groups demonstrating the tumorigenesis of CT26 cells to be higher than MC38 cells, 
which is consistent with previously published studies (117, 137-139). However, the 
minimal number of cells required for sufficient tumorigenesis varied among studies. 
Zigmond et al. (105) established an EGM within 3 weeks using 10
3
 MC38 cells reaching a 
mean endoscopic score of 3 after 3 weeks; Zhao et al. revealed that 10
4
 CT26 cells or 10
5
 
MC38 cells were not enough for primary tumor growth even after 4 weeks of observation 
(117); Bar-David et al. (140) and Rubinstein et al. (141) injected 10
4
 MC38 cells in another 
EGM, respectively. Tumors developed after 2 and 4 weeks, respectively. These 
inconsistence may be explained by variations in the viability of injected tumor cells or even 
genomic evolution across cell line strains, differences involved in the precision and 
success of injections (e.g., incorrect injection, trans-mural, intra-luminal), varied host 
reaction to the cells (142, 143). As for our research, the minimal cell number and 
observation period to establish a successful EGM were 10
4
 CT26 cells at 7 days of 
observation and 10
5
 MC38 cells at 14 days of observation.  
4.3 Lymph node and distant metastasis 
Regarding distant metastasis in orthotopic models, the reported take rates have been low. 
In fact, only few orthotopic studies reported spontaneous distant metastasis, and those 
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rates varied relevantly. Regarding CT26 and MC38 application in OSMs, Tan et al. 
reported 55% hepatic metastasis 10 weeks after MC38 cells injection (72). Kashtan et al. 
found 50% hepatic metastasis 4 weeks following CT26 injection (144), whereas Zhang Y 
et al. revealed 8% hepatic metastasis 8 weeks after CT26 injection (145). Zhang B et al. 
observed 10% hepatic metastasis 5 weeks after CT26 injection (146). Pulmonary 
metastasis only appeared in immune-deficient mice (69, 83). For CT26 and MC38 
application in EGM, Zigmond et al. were not able to detect distant spread 3 weeks after 
cell injection (105). In consistency with these publications, no pulmonary metastasis was 
found in the present study. In addition, no hepatic metastasis was found in 
MC38/C57BL/6J group which refers to its lower tumorgenicity regarding local primary 
tumor growth. In CT26/BALB/c group, the hepatic metastasis rate was 18% in EGM and 
20% in OSM, respectively, however, the difference was not significant. When 10
6
 CT26 
cells were injected, a hepatic metastasis of 25% was able to be achieved in the EGM 
animals. The shortest observation period with detection of metastasis was only one week, 
whereas it was two weeks in the OSM. We also observed early development of distant 
metastasis in up to 50% of mice on day 14 when more than 10
4
 CT26 was injected. The 
differences mentioned above suggest that CT26 cells show higher metastatic potential 
than MC38 cells. Although this difference was not reported by previous studies, some 
evidence exists indicating CT26’s high invasiveness as well as MC38’s rather poor 
invasiveness (139, 147). It should be noted that some liver metastasis were 
macroscopically evident as gray nodules on the liver surface whereas others were only 
visible and confirmed on serial histological sections. In this regard, radiological methods 
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such as positron emission tomography–computed tomography (PET-CT) or small animal 
magnetic resonance imaging (MRI) were shown to improve detection of metastasis, 
however, these techniques are complex and expensive (148-155). 
4.4 Assessment of TILs 
In the present study, assessment of TILs was performed for the first time in a murine CRC 
model. This may provide a foundation to use this syngeneic model for translational 
research regarding the interaction of the tumor and the immune system, e.g. therapy with 
checkpoint blockade. Our OSM showed a negative correlation between TILs score and 
metastasis demonstrating that TILs were more prominent in the early stages and 
decrease in the advanced stages. This is consistent with most cases in humans 
suggesting that TILs are an indicator for a better prognosis in CRC (134, 156). 
Furthermore, in the OSM presented in our study, it was revealed that the MC38/C57BL/6J 
group got significantly higher TILs scores than the CT26/BALB/c group, which may 
suggest a stronger antitumor immune response involved in the MC38/C57BL/6J group. 
This may also be part of the explanation why more MC38 cells were needed for sufficient 
tumorigenesis. On the other hand, the CT26/BALB/c group was scored significantly higher 
in the EGM. This discrepancy may be due to differences in the surgical trauma and the 
injection sites. Different microenvironment could lead to different immune profiles and 
responses to the same cell line. Of note, TILs score itself may not be sufficient to fully 
describe the organization and distribution of immune response. Further features such as 
the organization into tertiary lymphoid structures and the presence of hotspots combined 
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could provide a more precise picture of immune response (134).   
4.5 Technical aspects 
Although the present EGM is effective regarding tumor growth, some considerations 
should be kept in mind. 
Mice should be at least 10 weeks old thus to enable endoscope introduction without 
harming the animals. It should be noted that although two operators were optimal for the 
procedure, one operator was also able to perform the procedure alone after practice. 
As for injection needles, researchers picked different sizes ranging from 25G to 33G. To 
establish a standard procedure of tumor cell implantation in the mouse colon wall, we 
used 31G needle (Figure 2B). On one hand, its small diameter was observed to reduce 
the risk of perforation and avoid pneumoperitoneum even in the case of perforation, in 
addition, it also made slow and gentle injection possible, which helped to cause less harm 
to murine colon. On the other hand, it provided the rigidity needed for insertion and 
stability for injection.  
The flexible catheter (Figure 2B) attached to the needle was chosen after several tests, 
optimal wall thickness was evaluated on two aspects, on one hand, it was wide enough to 
carry the needle, on the other hand, it could roll within the sheath which facilitated the 
adjustment of needle bevel orientation in the colon.  
During colonoscopy, the endoscopic view could be obstructed by feces even after fasting 
(Figure 10A). Usually feces were moved proximally with gentle air inflation (Figure 10B), if 
not, 1 mL warm DPBS was applied to wash the colon. DPBS suited well lubricating the 
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endoscope to facilitate insertion. More than 2 mL DPBS led to blurry / bubble-filled view 
and this was associated with a higher risk of perforation. Tap water was avoided to clean 
the colorectum as the mucosa would become less transparent or even white.    
High air flow could harm the animal by over inflating the bowel, if the air flow was too low, 
the mucosa layer would get folded which makes a clear 360 degree view during cell 
injection impossible. Sometimes the mucosa got folded due to peristalsis (Figure 10C). 
Hence, it is important to consider that this is not due to a low air flow as only a few 
seconds are needed in this case for the peristaltic wave to pass (Figure 10D).   
The endoscopic score showed a positive correlation with primary tumor volume measured 
at autopsy, although no linear correlation was observed, colonoscopy is still a good 
non-invasive tool which can be used for early detection of obstruction or impending 
obstruction. Two mice reached score 3 and 4 at the second week and stayed alive in good 
condition with the same endoscopic score until the end of the observation, respectively. 
One possible reason was that these tumors invaded the submucosa and expanded 
excentrically towards the serosa (117). Therefore, wall transparency, mucosal bleeding 
and focal lesions should be considered together with the endoscopic score during 
follow-up colonoscopy. In addition, imaging of colonoscopy will be complicated around the 
tumor (endoscopic score ≥ 4) sites by restriction of the colorectal lumen. Hence, suitable 
time points of follow-up colonoscopy should be chosen if the EGM is used for antitumor 
treatment. 
Based on the great works of Becker et al. (107) and Kodani et al. (127), the valuable 
advices from pioneers and experts in the field of murine colonoscopy, Prof. Christoph 
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Becker and his team, Dr. Chen Varol and Frank Hipp, a checklist with practical tips for the 
establishment of this model is presented in Table 10 (128). 
 
 
Figure 10. Troubleshooting.  
If (A) feces obstructed the view, gentle air inflation or DPBS wash can be used for (B) 
better visibility. If (C) peristaltic movements are observed, wait till the wave pass through 













However, there are some potential limitations of the present study.  
Our study was limited to a syngeneic setting as only immune competent mice with 
injection of the respective murine cell lines were used. Although this kind of approach 
enables the assessment of the immune system such as TILs, human tumor xenograft 
studies in immune-deficient mice is still helpful, since cell lines / tumor tissues derived 
from CRC patients could mimic human CRC process more closely (143).  
Only basic functions of the colonoscopy were involved in our EGM, some add ons such as 
crypt pattern analysis using dye-aided colonoscopy which permits the discrimination 
between inflammatory and neoplastic changes, fluorescence colonoscopy which can be 
applied to better locate and visualize tumor growth were not included (107, 118). 
In our EGM, metastases were only analyzed during autopsy. BLI, PET-CT and small 
animal MRI were not used which can detect metastasis development in living mice (152, 
157). 
5. Conclusion 
In conclusion, we successfully established two syngeneic endoscopy-based CRC models 
and observed some advantages over the OSM as the current gold standard. The results 
presented in the current study could be used as a guideline for researches that are 
interested in the establishment of a syngeneic orthotopic mouse model for CRC research 
that overcomes some of the disadvantages of the OSM. Furthermore, the EGM provides 
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new possibilities such as minimally invasive follow-up endoscopies including tumor biopsy 
without the need for sacrificing the animals as well as new visualization techniques. Our 
results provide the researcher with details regarding the selection of cell line, cell number 
and observation period for specific research approaches. 
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